AUTL: Autolus Therapeutics plc Stocks News on November 22, 2024

Autolus Therapeutics upgraded to Buy from Neutral at Goldman Sachs

AUTL

TipRanks

3 days ago

Autolus Therapeutics upgraded to Buy from Neutral at Goldman Sachs

AUTL

MT Newswires

4 days ago

Goldman Sachs Upgrades Autolus Therapeutics to Buy From Neutral, Adjusts Price Target to $7.60 From $7

Autolus Therapeutics Third Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.26 loss in 3Q 2023)

AUTL

Simply Wall St.

7 days ago

Autolus Therapeutics Third Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.26 loss in 3Q 2023)

AUTL

MT Newswires

7 days ago

Redburn Atlantic Upgrades Autolus Therapeutics to Buy From Neutral, Price Target is $13

AUTL

GuruFocus.com

7 days ago

Syncona Ltd (LSE:SYNC) Half Year 2025 Earnings Call Highlights: Navigating Market Challenges ...

AUTL

GuruFocus.com

9 days ago

Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

AUTL

Thomson Reuters StreetEvents

9 days ago

Q3 2024 Autolus Therapeutics PLC Earnings Call

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

AUTL

GlobeNewswire

10 days ago

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

These Stocks Moved the Most Today: Tesla, DJT, Coinbase, MARA, Cigna, Humana, AbbVie, Super Micro, and More

AUTL

Barrons.com

11 days ago

These Stocks Moved the Most Today: Tesla, DJT, Coinbase, MARA, Cigna, Humana, AbbVie, Super Micro, and More

These Stocks Are Moving the Most Today: Tesla, DJT, Coinbase, MARA, Cigna, Humana, AbbVie, Super Micro, and More

AUTL

Barrons.com

11 days ago

These Stocks Are Moving the Most Today: Tesla, DJT, Coinbase, MARA, Cigna, Humana, AbbVie, Super Micro, and More

Autolus secures FDA approval for CAR-T cell therapy use in ALL

AUTL

Pharmaceutical Technology

11 days ago

Autolus secures FDA approval for CAR-T cell therapy use in ALL

AUTL

MT Newswires

11 days ago

Sector Update: Health Care Stocks Mixed Premarket Monday

AUTL

GuruFocus.com

11 days ago

What To Expect From Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings

FDA approves new CAR-T competitor to Gilead’s Tecartus

AUTL

BioPharma Dive

11 days ago

FDA approves new CAR-T competitor to Gilead’s Tecartus

AUTL

MT Newswires

14 days ago

Autolus Therapeutics' Leukemia Treatment Receives US FDA Approval

$Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)$

AUTL

GlobeNewswire

14 days ago

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations

AUTL

GlobeNewswire

17 days ago

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations

AUTL

Simply Wall St.

19 days ago

Further weakness as Autolus Therapeutics (NASDAQ:AUTL) drops 21% this week, taking five-year losses to 71%

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

AUTL

GlobeNewswire

25 days ago

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

AUTL

Insider Monkey

a month ago

Autolus Therapeutics (AUTL): High-Growth UK Stock in Cancer Therapy

Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress

AUTL

GlobeNewswire

a month ago

Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress

AUTL

Insider Monkey

a month ago

Why Autolus Therapeutics plc (AUTL) is the Penny Stock with the Biggest Upside Potential According to Analysts

AUTL

GuruFocus.com

a month ago

Autolus Therapeutics PLC (AUTL) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...

Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer

AUTL

GlobeNewswire

2 months ago

Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer

AUTL

MT Newswires

2 months ago

Autolus Therapeutics to Amend Lease at Nucleus Manufacturing Facility in UK

AUTL

Insider Monkey

2 months ago

Autolus Therapeutics PLC (AUTL): Fast-Growing Penny Stock To Consider

AUTL

Insider Monkey

3 months ago

Autolus Therapeutics plc (AUTL): The Best Multibagger Penny Stock of 2025?

Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024

AUTL

GlobeNewswire

3 months ago

Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024

AUTL

Simply Wall St.

3 months ago

Autolus Therapeutics (NASDAQ:AUTL) Is In A Good Position To Deliver On Growth Plans

AUTL

MT Newswires

3 months ago

Autolus Therapeutics Q2 Loss Narrows; Shares Fall

Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

AUTL

GlobeNewswire

3 months ago

Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

AUTL

GlobeNewswire

4 months ago

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

$Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress$

AUTL

GlobeNewswire

5 months ago

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

AUTL

GlobeNewswire

6 months ago

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

AUTL

Thomson Reuters StreetEvents

6 months ago

Q1 2024 Autolus Therapeutics PLC Earnings Call

AUTL

MT Newswires

6 months ago

Autolus Therapeutics' Q1 Loss Widens, Licensing Revenue Rises

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

AUTL

GlobeNewswire

6 months ago

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

$Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress$

AUTL

GlobeNewswire

6 months ago

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

AUTL

MT Newswires

6 months ago

Autolus Therapeutics Announces Delay of Q1 Earnings Release

Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call

AUTL

GlobeNewswire

6 months ago

Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call

AUTL

Simply Wall St.

7 months ago

Recent 13% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still up 157% over 1 year

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

AUTL

GlobeNewswire

7 months ago

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

AUTL

GlobeNewswire

7 months ago

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

$Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)$

AUTL

GlobeNewswire

8 months ago

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Autolus Therapeutics Announces Changes to its Board of Directors

AUTL

GlobeNewswire

8 months ago

Autolus Therapeutics Announces Changes to its Board of Directors

AUTL

Thomson Reuters StreetEvents

8 months ago

Q4 2023 BioNTech SE Earnings Call

AUTL

Insider Monkey

8 months ago

Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2023 Earnings Call Transcript

Autolus Therapeutics Full Year 2023 Earnings: EPS Misses Expectations

AUTL

Simply Wall St.

8 months ago

Autolus Therapeutics Full Year 2023 Earnings: EPS Misses Expectations

AUTL

Thomson Reuters StreetEvents

8 months ago

Q4 2023 Autolus Therapeutics PLC Earnings Call

AUTL

GuruFocus.com

8 months ago

Autolus Therapeutics PLC Reports Full Year 2023 Financial Results

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

AUTL

GlobeNewswire

8 months ago

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

AUTL

GlobeNewswire

8 months ago

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

Autolus Therapeutics announces publication in Blood Cancer Journal

AUTL

GlobeNewswire

8 months ago

Autolus Therapeutics announces publication in Blood Cancer Journal

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

AUTL

GlobeNewswire

9 months ago

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

Autolus Therapeutics announces publication in Nature Communications

AUTL

GlobeNewswire

9 months ago

Autolus Therapeutics announces publication in Nature Communications

AUTL

Simply Wall St.

9 months ago

Autolus Therapeutics plc's (NASDAQ:AUTL) institutional investors lost 8.1% last week but have benefitted from longer-term gains

Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?

AUTL

Zacks

9 months ago

Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?

AUTL

Zacks

9 months ago

Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength?

Autolus Announces Pricing of Underwritten Offering

AUTL

GlobeNewswire

9 months ago

Autolus Announces Pricing of Underwritten Offering

BioNTech partners with Autolus to boost cell therapy manufacturing

AUTL

BioPharma Dive

9 months ago

BioNTech partners with Autolus to boost cell therapy manufacturing

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

AUTL

GlobeNewswire

9 months ago

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains?

AUTL

Zacks

10 months ago

2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains?

JetBlue's (JBLU) Q4 Loss Narrower Than Expected, Q1 View Weak

AUTL

Zacks

10 months ago

JetBlue's (JBLU) Q4 Loss Narrower Than Expected, Q1 View Weak

Why Medical Properties Trust Stock Tumbled on Tuesday

AUTL

Motley Fool

10 months ago

Why Medical Properties Trust Stock Tumbled on Tuesday

Has Fastenal Company's (NASDAQ:FAST) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

AUTL

Simply Wall St.

10 months ago

Has Fastenal Company's (NASDAQ:FAST) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Varonis Extends Data Security Posture Management Coverage to Snowflake

AUTL

GlobeNewswire

10 months ago

Varonis Extends Data Security Posture Management Coverage to Snowflake

Trustmark (TRMK) Q4 Earnings and Revenues Top Estimates

AUTL

Zacks

10 months ago

Trustmark (TRMK) Q4 Earnings and Revenues Top Estimates

Wall Street Analysts Believe Harmony Biosciences Holdings, Inc. (HRMY) Could Rally 28.77%: Here's is How to Trade

AUTL

Zacks

10 months ago

Wall Street Analysts Believe Harmony Biosciences Holdings, Inc. (HRMY) Could Rally 28.77%: Here's is How to Trade

Recent Price Trend in Kiniksa Pharmaceuticals, Ltd. (KNSA) is Your Friend, Here's Why

AUTL

Zacks

10 months ago

Recent Price Trend in Kiniksa Pharmaceuticals, Ltd. (KNSA) is Your Friend, Here's Why

Autolus Therapeutics announces publication in ACS Chemical Biology

AUTL

GlobeNewswire

10 months ago

Autolus Therapeutics announces publication in ACS Chemical Biology

Beal Bank Provides $637.5 million of $885.0 million in New Debt to ProFrac Holding Corp (NASDAQ: ACDC) and its Subsidiaries

AUTL

PR Newswire

10 months ago

Beal Bank Provides $637.5 million of $885.0 million in New Debt to ProFrac Holding Corp (NASDAQ: ACDC) and its Subsidiaries

$Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)$